Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

Published:2021-01 Issue:1 Volume:16 Page:162-168
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Awad Mark M.,Gadgeel Shirish M.,Borghaei Hossein,Patnaik Amita,Yang James Chih-Hsin,Powell Steven F.,Gentzler Ryan D.,Martins Renato G.,Stevenson James P.,Altan Mehmet,Jalal Shadia I.,Panwalkar Amit,Gubens Matthew,Sequist Lecia V.,Saraf Sanatan,Zhao Bin,Piperdi Bilal,Langer Corey J.

Funder

Bristol-Myers Squibb

AstraZeneca

Lilly

Genentech

Merck

Millennium

Celgene

Merck Sharp & Dohme

Takeda Pharmaceuticals

Pfizer

Helsinn

EMD Serono

Novartis

GlaxoSmithKline

Astex Pharmaceuticals

OncoMed Pharmaceuticals

Roche

Boehringer Ingelheim

Loxo Oncology

Clovis Oncology

Inovio Pharmaceuticals

ARIAD Pharmaceuticals

Takeda

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference6 articles.

1. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study;Langer;Lancet Oncol,2016

2. 24-Month overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer;Borghaei;J Thorac Oncol,2019

3. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

4. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer;Gadgeel;J Clin Oncol,2020

5. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study;Garon;J Clin Oncol,2019

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. STING-Activating Polymer–Drug Conjugates for Cancer Immunotherapy;ACS Central Science;2024-08-19

2. Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial Efficacy;Journal of Medicinal Chemistry;2024-08-01

3. The role of immunotherapy in patients with lung cancer and brain metastases: a narrative review of the literature;Monaldi Archives for Chest Disease;2024-07-26

4. The efficacy outcomes in non-small cell lung cancer patients treated with PD axis inhibitor agents - a population-based study of the Vojvodina region;Pathology and Oncology Research;2024-07-12

5. Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis;Frontiers in Immunology;2024-07-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3